文献速递妇科

并非所有子宫癌肉瘤都相同:子宫癌肉瘤分子特征与生存结局的关系

Not all uterine carcinosarcomas are created equal: Survival outcomes according to molecular characterization of uterine carcinosarcoma.
PubMed 文献 · Gynecol Oncol · 2025-01-20

该研究纳入2235例子宫癌肉瘤(UCS)和6469例子宫内膜样癌(EEC),采用ProMisE分子分型及二代测序、全外显子测序和RNA检测,比较各分子亚型生存结局。UCS中TP53突变型最常见(78.2%),POLE突变型中位总生存期最长(74.8个月),TP53突变型和TP53野生型UCS的中位总生存期均劣于相应EEC亚型;POLE突变型和MSI-H型UCS与相应EEC亚型的生存无统计学差异。

要点

  • UCS中TP53突变型最常见,占78.2%(n=1402)。
  • UCS的POLE突变型中位OS为74.8个月,显著长于其他亚型(p<0.01)。
  • TP53突变型UCS中位OS 27.9个月,劣于TP53突变型EEC的35.3个月(HR 1.3;p=0.01)。

核心结论

  • TP53突变型是UCS最常见的分子亚型。
  • UCS按分子分型呈现分层生存,与EEC生存模式相似。
  • 尽管UCS被认为组织学更具侵袭性,POLE突变型和MSI-H型UCS与相应EEC亚型的生存无统计学差异。

研究设计与样本

  • 研究纳入2235例UCS和6469例EEC肿瘤样本,采用DNA二代测序、全外显子测序和RNA检测。
  • MSI通过免疫组化和NGS检测。
  • 真实世界总生存期(OS)来自Caris Life Sciences数据库,并与保险理赔数据配对。
  • 采用Cox比例风险模型计算风险比(HR),采用对数秩检验计算p值。

主要发现

  • 2235例UCS样本中,POLE突变型占2.7%(n=48),MSI-H型占7.4%(n=132),TP53突变型占78.2%(n=1402),TP53野生型占11.7%(n=210)。
  • UCS的POLE突变型中位OS为74.8个月(95%CI:30.5个月至未达到),显著长于所有其他亚型(p<0.01)。
  • POLE突变型UCS与POLE突变型EEC的化疗后中位OS无差异(p=0.75);MSI-H型UCS与MSI-H型EEC的化疗后中位OS无差异(p=0.14)。
  • TP53突变型UCS与TP53突变型EEC的中位OS分别为27.9个月与35.3个月(HR 1.3,95%CI 1.1-1.5;p=0.01);TP53野生型UCS与TP53野生型EEC的中位OS分别为29.4个月与70.7个月(HR 2.0,95%CI 1.5-2.7;p<0.01)。
  • HER2阴性UCS与HER2阴性EEC的化疗后中位OS分别为32.9个月与77个月(HR 1.60,95%CI 1.092-2.348;p=0.02)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess if ProMisE classifier molecular subtypes are associated with differing survival outcomes in uterine carcinosarcoma (UCS) and compare these outcomes to endometrioid endometrial cancer (EEC) tumors. METHODS: There were 2235 UCS and 6469 EEC tumors using next-generation sequencing of DNA, whole exome sequencing, and RNA. Microsatellite instability (MSI) was tested by IHC and NGS. Real-world overall survival (OS) was obtained from Caris Life Sciences database and paired with insurance claims data. Hazard ratios (HR) were calculated using the Cox proportional hazards model, and p-values were calculated using the log-rank test. RESULTS: Of the 2235 UCS samples, 2.7 % (n = 48) were POLE mutant (MT), 7.4 % (n = 132) MSI-H, 78.2 % (n = 1402), TP53 MT, and 11.7 % (n = 210), TP53 wild type (WT). In UCS POLE MT tumors, median OS (74.8 mos; 95 % CI: 30.5-not reached [NR]; p < 0.01) was significantly longer than all other subtypes. There was no difference in median post-chemo OS between POLE MT UCS and POLE MT EEC (p = 0.75) or MSI-H UCS and MSI-H EEC (p = 0.14). TP53 MT UCS and TP53 WT UCS tumors had worse median OS compared their respective ECC subtypes (27.9 vs 35.3 mos; HR: 1.3 95 % CI (1.1-1.5); p = 0.01, 29.4 vs 70.7 mos; HR: 2.0 95 % CI (1.5-2.7); p < 0.01). HER2 negative UCS had worse post-chemo OS compared to HER2 negative EEC (32.9 vs 77 mos; HR 1.60 95 % CI (1.092-2.348); p = 0.02). CONCLUSION: TP53 MT is the most common molecular UCS sub-type. Overall, UCS has tiered survival according to molecular classification, which mirrors EEC survival patterns. Despite UCS being considered a more aggressive histology, POLE MT and MSI-H outcomes when comparing UCS and EEC were not statistically different.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Toboni MD, Dinkins K, Wu S, et al. Not all uterine carcinosarcomas are created equal: Survival outcomes according to molecular characterization of uterine carcinosarcoma. Gynecol Oncol. 2025. PMID: 39837013. doi:10.1016/j.ygyno.2024.12.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。